Peptides are exploding — and the business, legal, and regulatory landscape is changing fast.
In this episode of Pep Talk, Gregory sits down with Dustin Robinson, known as “the peptide lawyer,” to break down the booming peptide industry, from GLP-1 telehealth companies and 503A compounding pharmacies to research-use-only peptide brands and the gray areas shaping the market.
Dustin explains why demand is outpacing regulation, how young founders are building multi-million-dollar peptide businesses, what the FDA is watching, and why the future may shift more toward medical and telehealth pathways. They also discuss BPC-157, TB-500, semaglutide, tirzepatide, retatrutide, payment processing, affiliate marketing risks, Big Pharma, RFK Jr., and what peptide entrepreneurs need to understand before scaling too quickly.
A must-listen for anyone interested in peptides, longevity, GLP-1s, health optimization, biotech, telehealth, emerging regulated industries, or the future of decentralized healthcare.
Timestamps:
00:00 — The Peptide Gold Rush
05:00 — Telehealth, 503A Pharmacies & GLP-1s
10:00 — Big Pharma, Patents & Innovation
15:00 — Category Two, Category One & FDA Process
20:00 — Why Natural Peptides Are Hard to Patent
25:00 — Young Founders Making Millions
30:00 — COAs, Purity & China Manufacturing
35:00 — Peptides, Longevity & Decentralized Health
40:00 — Dustin’s Personal Peptide Experience
45:00 — RUO Compliance & Lines Not to Cross
50:00 — Will RUO Peptides Go Away?
55:00 — Affiliate Marketing & Telehealth Risks
1:00:00 — How Telehealth Companies Are Structured